The influence of growth hormone (GH) on splanchnic exchange of glucose and glucogenic precursors was investigated in 11 healthy subjects using the hepatic venous catheter technique. GH was infused intravenously at the rate of 40 \g=m\g/kgbody weight over 30 min. A peak plasma GH level of 219 \ m=+-\25 ng/ml was obtained. During GH infusion the blood glucose concentration fell slightly but significantly. In addition, the splanchnic glucose output decreased by approximately 35\p=n-\40 % during and immediately after GH infusion. The splanchnic uptake of the glucogenic precursors lactate, pyruvate, alanine and glycerol was not significantly influenced by GH infusion. The arterial concentration of insulin fell slightly, while the glucagon level remained unchanged during the infusion but decreased 20\p=n-\30 min after the end of GH infusion. Indirect estimates of the peripheral glucose utilization indicated that GH infusion was accompanied by a 25 % reduction in peripheral glucose uptake. The influence of GH on the inhibition of splanchnic glucose output induced by endogenous insulin in connection with intravenous glucose infusion (2 mg/kg/min) was studied in 6 subjects. GH infusion, given 60 min before the onset of glucose administration, did not significantly modify the splanchnic glucose output response to glucose infusion.
Growth hormone (GH) exerts complex effects on carbohydrate metabolism. Its diabetogenic action has been documented in detail by several investigators, and constitutes the classical action of GH on glucose homoeostasis (for reviews, see Kipnis 1965; Adamson 1975 ). However, it has been known since many decades that GH may also induced hypoglycaemia and thus mimic the action of insulin (Marx et al. 1944; Kurtz et (Wahren 1966) , pyruvate (Segal et al. 1956 ), glycerol (Wieland 1962) , and alanine (Karl et al. 1972) i-, (Cerasi et al. 1966) , plasma glucagon by the charcoal separation radioimmunoassay (Faloona 8c Unger 1974), using an antibody specific for pancreatic glucagon (30 K. kindly provided by Dr. Roger Unger, Dallas, Texas). Cyclic AMP in plasma was measured by protein binding assay (Gilman 1970 (Snedecor 1956 ), employing the paired ¿-test when applicable.
RESULTS
The mean arterial concentration of GH, estimated from blood samples taken immediately after and 15 min after the hepatic catherization procedure, was 5 ± 1 ng/ml. The concentration rose gradually throughout the infusion of the hormone, reaching a peak level of 219 ± 25 ng/ml at the end of the 30 min infusion period (Table 1) . After this, GH in plasma decreased with an approxi¬ mate half-life of 18 min. Sixty min later, at the start of the glucose infusion, the plasma GH level was 30 ± 7 ng/ml. The hepatic venous concentration of GH was consistently lower than the arterial one, reaching statistical significance at 30 min (198 ± 28 vs. 219 ± 25 ng/ml, P < 0.05).
Infusion of GH had no significant effect on the estimated hepatic blood flow (Table 1 ). The GH-infusion was accompanied by a small fall in the arterial glucose concentration (Fig. 1) (Fig. 1 and Table 1 ).
This "insulin-like" effect of GH diminished with time, as the arterial glucose as well as the splanchnic glucose output returned to the basal levels in the six subjects studied up to 90 min after GH (Fig. 1) . (Table 2 ).
In Fig. 2 The liver and the peripheral tissues are possible sites of action of GH. The present study suggests that the liver is the main target for the "insulin-like" effect of GH. The reduction of splanchnic glucose output occurred simultane¬ ously with the decrease in blood glucose concentration. However, the relatively small change in blood glucose, in combination with the 30-40°/o inhibition of splanchnic glucose production suggests that the peripheral utilization of glucose was reduced in connection with GH infusion. In fact, the estimated peripheral (1970) demonstrated that GH reduces the efficiency of insulin in vivo. Synergism between GH and insulin has not been described. The effect of endogenous insulin on splanchnic glucose production (Table 3) was neither enhanced nor diminished by GH. However, in these experiments glucose infusion was started 60 min after the end of GH administration, at a time when the GH effect on the liver had already disappeared (Fig. 1) . Thus, a synergistic action between GH and the basal level of insulin cannot be excluded.
The results presented here were obtained with pharmacological doses of GH. However, we have previously shown (Adamson 8c Cerasi 1975« ) that much smaller doses of GH (5 /yg/kg), inducing peak plasma levels around 25 ng/ml, are associated with a similar blood glucose lowering effect. We therefore suggest that the effect of GH on splanchnic glucose balance in the present study may have a counterpart under physiologic conditions, when GH in blood is known to fluctuate markedly.
